{"id":"NCT00720278","sponsor":"Meda Pharmaceuticals","briefTitle":"A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies","officialTitle":"Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 and MP03-33 Compared to Placebo in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2007-10","completion":"2007-11","firstPosted":"2008-07-22","resultsPosted":"2009-10-27","lastUpdate":"2010-03-02"},"enrollment":526,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"0.15% azelastine hydrochloride 1644 mcg daily","otherNames":["Astepro 0.15%"]},{"type":"DRUG","name":"0.1% azelastine hydrochloride 1096 mcg daily","otherNames":["Astepro 0.1%"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo Nasal Spray","type":"PLACEBO_COMPARATOR"},{"label":"Astepro 0.1%","type":"EXPERIMENTAL"},{"label":"Astepro 0.15%","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to determine if two allergy medications are more effective than placebo.","primaryOutcome":{"measure":"Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo","timeFrame":"baseline and 14 days","effectByArm":[{"arm":"Placebo","deltaMin":17.86,"sd":3.301},{"arm":"Astepro 0.1%","deltaMin":18.29,"sd":3.23},{"arm":"Astepro 0.15%","deltaMin":17.83,"sd":3.284}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":178},"commonTop":["Dysgesusia","Nasal Discomfort"]}}